6:09 PM
 | 
Feb 06, 2013
 |  BC Extra  |  Politics & Policy

EU Parliament sets 90 days for pricing generics

The European Parliament adopted a proposed Transparency Directive that will require member states to make pricing and reimbursement decisions on generic and biosimilar products within 90 days of approval. The timeline is longer than the 60 days that was included in a proposed directive that was...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >